I really prefer not to predict time lines, especially based on best case scenario. That said, If K has a DLT in Cohort 8, and MTD becomes 165 mg/m2, then Cohort 9 is the final one and end of trial is 6 months after finish of Cohort 9. Add it all up and K finishes in December to February.
B goes until September (I already said I thought it would finish earlier given the region and people), then the Phase 2b report can be ready before December and a license, if a license is desired, could be finalized this time 2015, if not earlier. Phase 3 will take 6 months after the end of data collection, minimal.
P is short and sweet. Confirmation of conversion to Abacavir will be in 45 to 60 days and Phase 2/3 can begin as soon as the FDA approves it. I agree with Gov, Leo et al probably have it already set up and ready to go following FDA clearance.
The market works 6 months in advance, so we should see positive movement as soon as biopharma sector reverses.
News 
Market Data 
Discover 
